Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome

• Status: Unknown status
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators designed a compassionate basis phase II study for refractory/relapsed mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation of overall response and time to relapse. Other goals to consider are toxicity and time to new therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Latin American Cooperative Onco-Haematology Group - Peru
• Treatments: Alemtuzumab

Criteria

Inclusion Criteria:

• Above 18 years old

• Eastern Cooperative Oncology Group (ECOG) 0-2

• Liver and renal function test less than twice upper label

• No active infection

• Written informed consent

• One to three regimens of previous chemotherapies

Exclusion Criteria:

• Abnormal renal or hepatic function

• Mycosis fungoides/Sezary syndrome in transformation

• HIV +

• HTLV-1 +

• Pregnancy

• Lactation